Archie Goodburn, a 24-year-old British swimmer battling a rare and aggressive form of brain cancer, is passionately advocating for increased government action and funding to support research into his condition. With a recent breakthrough treatment allowing him to continue competing, Goodburn highlights that the UK has made little progress in the development of new drugs for brain cancer in the past two decades, urging policymakers to prioritise this critical area of healthcare.
A Life Transformed by Diagnosis
Two years ago, Goodburn’s promising swimming career faced an unexpected and devastating turn. Just months before he aimed to qualify for the Paris Olympics, he began experiencing alarming symptoms during training, including unexplained weakness, numbness on his left side, and a profound sense of fear and nausea. “I felt like my consciousness was being pulled away from me,” he recalled, as his condition rapidly deteriorated.
In April 2024, his devastating diagnosis was confirmed: three oligodendrogliomas, rare tumours that account for approximately 3% of all brain cancer cases. This diagnosis not only halted his Olympic aspirations but also marked the beginning of a challenging journey filled with uncertainty.
A Breakthrough Treatment
Fortunately, Goodburn recently gained access to Vorasidenib, a cutting-edge treatment that has provided him with a renewed opportunity to compete, specifically at the Commonwealth Games set to take place in Glasgow next month. This drug has successfully postponed the need for chemotherapy and radiotherapy—treatments that could have severely impacted his cognitive abilities and disrupted his rigorous training schedule, as well as his pursuit of a chemical engineering degree.
However, Goodburn remains resolute in his belief that one new treatment in twenty years is insufficient. “Vorasidenib only bought me four years, according to the trials. I need more. And I’m not going to stop campaigning until my last breath,” he declared, underscoring the urgency of the situation.
Advocacy for Change
Despite being the leading cause of cancer-related deaths among children and adults under 40, brain cancer has received a meagre 1% of the UK government’s national cancer research budget since 2002. Goodburn is vocal about the “translational gap” that exists between groundbreaking research and the clinical trials that patients desperately need. He points out that while research is ongoing, the transition from discovery to accessible treatment remains perilously slow.
The all-party parliamentary group on brain tumours refers to this gap as the “valley of death,” attributing it to a risk-averse funding system that complicates the pursuit of effective treatments. Even when funding is allocated, red tape often hinders its proper utilisation. For instance, a mere fraction of the £40 million promised by the government for brain cancer research in 2018 has actually been put to use.
Goodburn, along with the Brain Cancer Justice campaign, is calling for the immediate release of the remaining funds, ensuring they reach the scientists on the front lines. They are also advocating for the appointment of a dedicated brain cancer lead within the government, increased genome sequencing for patients, and the establishment of a “right to try” policy for potentially life-saving treatments.
Government Response and Future Aspirations
In response to these pressing petitions, the Department of Health and Social Care acknowledged the need for more robust research into brain tumours and expressed its commitment to ensuring patient access to innovative medicines. However, many remain sceptical about the pace of change.
Goodburn’s own journey with Vorasidenib has been remarkable; shortly after beginning treatment, he set a new Scottish record in the 50m breaststroke, the event in which he will compete at the upcoming Commonwealth Games. This achievement has reinforced his belief in the transformative potential of new treatments and the necessity of advocating for better care.
As he prepares to step into the arena in Glasgow—having watched the 2014 Commonwealth Games as a child—Goodburn is also gearing up for a significant challenge: attending a debate in Westminster where MPs will discuss the petition he and Brain Cancer Justice have tirelessly campaigned for. Balancing rigorous training with advocacy has not been easy, but Goodburn remains undeterred.
“I campaign, if I’m being completely honest, because of the disparity in care, the lack of funding, but also because I believe that my campaigning can actually make a difference to my own future,” he stated emphatically. “In some ways, it’s a treatment of its own.”
Why it Matters
Goodburn’s story sheds light on a critical issue that has long been overlooked: the urgent need for increased funding and support for brain cancer research. His advocacy not only represents the struggles of countless individuals affected by this devastating disease but also challenges the status quo of healthcare funding. As he fights for his own future and that of others, his efforts could catalyse significant change, potentially transforming the landscape of brain cancer treatment in the UK. The time for action is now, and the consequences of inaction could be dire for many.
